Electronic Supplementary Material 1

Article Title

Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Post Marketing Prospective Cohort Study in England in the 2014-15 season

Journal

Drug Safety

Authors

Rhian McNaughton, Elizabeth Lynn, Vicki Osborne, Abigail Coughtrie, Deborah Layton, Saad Shakir

Corresponding author

Dr Rhian McNaughton
Drug Safety Research Unit (DSRU)
Bursledon Hall
Blundell Lane
Southampton
SO31 1AA
United Kingdom
rhianejones@hotmail.com

PARENT/LEGAL GUARDIAN **INFORMED CONSENT FORM**

Please send this form back to the DSRU together with any assent forms your child may have signed, if appropriate.



A Postmarketing Noninterventional Cohort Study of the Safety of Live Attenuated Influenza Vaccine (LAIV) in Subjects 2 Through 17 Years of Age.

Patient Study Identification Code

Vaccination Site Identification Code

PSIC: P

VSIC: V

N	//	Λ	П	R	All I	C		ı	All.	C	M		0	D	A	Л
ш	78	м	ш	H.	W.		u	41	w	2	IIV	 - 15	v		ш	71

AIN CONSENT FORM									
PATIENT DETAILS >	Personal details of person vacc	inated (vaccinee)							
	Forename:								
	Surname:								
	Date of birth:		Gender:						
	NHS number (if known):								
	Personal details of representat	ive (e.g. parent/gı	uardian/next of kin) of person vaccinated						
	Forename:								
	Surname:								
	Address:								
	Relationship to person vaccin	ated:							
	Email Address:								
	Contact telephone number:								
	State the preferred method for	completion of stu	udy questionnaires:						
	Paper (Surface mail):		Email:						
	I wish to receive a pre-paid vo	oucher for my part	cicipation in the study						
	I do not wish to receive a pre- children's charity of their choi	•	would like the DSRU to donate to a						
			Please initial boxes b	elow ▼					
FORM ►		to consider the info	e information sheet for the above study. I ormation and ask questions, and have had						
	I understand that my child's participation is voluntary and that my child is free to withdraw at any time, without giving any reason, without their medical care or legal rights being affected.								
	3. I give permission for releva their GP or other care team		d's GP medical charts to be accessed by n with this study.						



П



MAIN CONSENT FORM

	Please initial box b	elow ▼
4.	I agree to my child's GP being contacted to find out more information about any side effects experienced following vaccination.	
GP	CONTACT DETAILS	
Na	ame:	
Ad	ddress:	
Ро	stcode:	
Tel	lephone No:	
	Please initial boxes b	elow ▼
5.	I agree to information, from which my child can be identified, being held by the research team at the Drug Safety Research Unit together with data collected during the study.	
6.	I agree for my child to take part in the study.	
7.	I agree for the research team to contact me in the future about further Drug Safety Research studies.	
Nar	me of child	
Nar	me of child's legal representative (PRINT) Signature Date	
• • • • •		
Pati	ient Study Identification Code	
PS	SIC: P	
Vac	cination Site Identification Code	
VS	SIC: V	



Drug Safety Research Unit Bursledon Hall, Blundell Lane, Southampton, Hampshire SO31 1AA Tel: (023) 8040 8600 www.dsru.org **Please return to:** Flu Vaccine Feedback study, FREEPOST RTJZ-CHEH-HKRH, Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, Hampshire, SO31 1AA. Tel: (023) 8040 8600

INFORMED CONSENT FORM FOR PARTICIPANTS AGED 16-17 YEARS

Please send this form back to the DSRU



A Postmarketing Noninterventional Cohort Study of the Safety of Live Attenuated Influenza Vaccine (LAIV) in Subjects 2 Through 17 Years of Age.

Patient Study Identification Code

PSIC: P

Vaccination Site Identification Code

VSIC: V

M	A		V	C	0	N	S	톄	N	Т	F	0	R	M
	D	Δ	T	ΙĒ	N	т	Г) F	Ť	Δ.	п	S		

Pers	sonal details of person vaccinated (vaccinee)					
Fo	rename:					
Su	rname:					
Da	te of birth: Gender:					
NH	S number (if known):					
Ad	dress:					
Em	ail address:					
Со	ntact telephone number:					
C4-4						
	e the preferred method for completion of study questionnaires:					
Pa	per (Surface mail):	ш				
I wish to receive a pre-paid voucher for my participation in the study						
	o not wish to receive a pre-paid voucher and would like the DSRU to donate to a Ildren's charity of their choice on my behalf					
	Please initial boxes b	elow ▼				
1.	I confirm that I have read and understand the information sheet for the above study. I have had the opportunity to consider the information and ask questions, and have had these answered satisfactorily.					
2.	I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected.					
3.	I give permission for relevant parts of my GP medical charts to be accessed by my GP or other care team staff in connection with this study.					
4.	I agree to my GP being contacted to find out more information about any side effects experienced following vaccination					
GP	CONTACT DETAILS					
Na	me:					
Ad	dress:					
Po	stcode:					



INFORMED CONSENT

FORM ▶



			Please initial boxes be	low ▼
5.	_	on, from which I can be identified, be fety Research Unit together with dat		
6.	l agree to take part	in the study.		
7.	I agree for the resea Research studies.	rch team to contact me in the future	about further Drug Safety	
Nar	ne (PRINT)	Signature	Date	
• • • •				• • • • • •
Pati	ent Study Identificatio	n Code (PSIC)		
PS	SIC: P			
Vac	cination Site Identifica	tion Code (VSIC)		
VS	SIC: V			
Ple	ase return to : Flu Vac	cine Feedback study, FREEPOST_RTJ2	Z-CHEH-HKRH,	
		it, Bursledon Hall, Blundell Lane, Sou		1AA.



Drug Safety Research Unit Bursledon Hall, Blundell Lane, Southampton, Hampshire SO31 1AA Tel: (023) 8040 8600 www.dsru.org Tel: (023) 8040 8600

Return Address: Flu Vaccine Feedback study, FREEPOST RTJZ-CHEH-HKRH, Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, Hampshire, SO31 1AA



A Postmarketing Noninterventional Cohort Study of the Safety of Live Attenuated Influenza Vaccine (LAIV) in Subjects 2 Through 17 Years of Age.

Please fill out form below and send to the address above or in the pre printed envelope provided

ENROLMENT QUESTIONNAIRE PSIC: P Has the vaccinee had the nasal 'flu vaccination? VACCINATION DETAILS Yes ▼ No If **YES**, specify date of vaccination: Location (address) of vaccination site: Did the vaccinee have another vaccination on the same day as the nasal 'flu vaccine? Yes ▼ If YES, specify vaccine name: Has the vaccinee had any other vaccines in the last month? Yes ▼ No If YES, provide further information on the type of vaccination and date? Vaccine name: Date: MEDICAL CONDITIONS Does the vaccinee have any of the following chronic underlying medical conditions (as diagnosed by a medical professional)? Asthma Yes No Diabetes Yes No Heart disease Yes No Chronic kidney disease Yes No **Immunosuppression** Yes No Moderate/severe liver disease Yes No Blood disorder Yes No Is the vaccinee currently pregnant? PREGNANCY Yes V No

If YES, provide expected date of delivery Date:



ENROLMENT QUESTIONNAIRE

MEDICATION	Does the vaccine	e take any medicines prescrib	oed by the doctor or	over-the-counter medicines?
	Yes ▼		□ No	
	If YES , give deta	ils of medicines in the table	below:	
		Name of Medicine	Dose	How often taken
	Medicine 1			
	Medicine 2			
	Medicine 3			
	Medicine 4			
	Medicine 5			
FURTHER CONTACT		for us to contact you again to ng the vaccination?	o find out more infor	rmation about any reported
	Yes		□ No	
		for us to contact the vaccine at prescriptions and any poss		
	Yes		□ No	
	c. Are you happy	for us to contact you again ir	future about furthe	er drug safety research studies?
	Yes		□ No	
	Thank you for	completing this questior	ınaire	



Return Address: Flu Vaccine Feedback study, FREEPOST RTJZ-CHEH-HKRH, Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, Hampshire, SO31 1AA



A Postmarketing Noninterventional Cohort Study of the Safety of Live Attenuated Influenza Vaccine (LAIV) in Subjects 2 Through 17 Years of Age.

Please fill out form below and send to the address above

DAW.	14 Ol	IFCT	AIDE
			Λ IPF

S

YMPTOMS SINCE	Did the vaccinee experience any of the following, either on the day of vaccination (after being
VACCINATION	vaccinated) or during the subsequent 14 days?

PSIC: P

	No	Yes	Date* symptom started	Date symptom stopped
High temperature (i.e. greater than 38.0°C)		□		
If YES , then give temperature recorded, if available:	tem	p:		
Nausea and vomiting				
Generally feeling unwell (malaise)				
Headache				
Decreased appetite				
Rash				
Muscle pain or joint pain				
Itchy or red eyes				
Any of the following: Swelling of the face, lips or tongue, difficulty breathing, feeling of dizziness/ light-headedness, general itchiness with a rash				
Wheezing				
Nasal congestion / runny nose				
Mouth or throat pain				
Cough				
Nosebleed				
Increased irritability (if the child is between two and four years)				
Increased crying (if the child is between two and four years)				



*If you're unsure of the date, provide the approximate number of days after vaccination when the symptom started and how long (how many days) symptoms lasted.



DAY 14 QUESTIONNAIRE

	Are there any other sym	ptoms that the vaccinee ha	as experienced sin	ce vaccination?
	Yes ▼		No	
	If YES , give details of s	ymptoms and date sympto	oms started:	
MEDICATION				
	Has the vaccinee visited	I the GP about any of the sy	mptoms listed ab	ove?
	Yes		No	
				f the symptoms listed above?
	Has the vaccinee been a	ndmitted to hospital with a	ny of the sympton	ns listed above?
	Yes		No	
MEDICATION	Have there been any ch	anges to the vaccinee's me	dication since rece	iving the vaccination ?
MEDICATION	Yes ▼		No	
	If YES , give details of n	nedicines and date of chan	nge	

Thank you for completing this questionnaire





GP FOLLOW-UP QUESTIONNAIRE

PSIC: P

Yes ▼			No									
If YES , provide any fu	rther details you ha	ve of th	e event, inc	ludin	g:							
Date of onset of event	t:		d	d	/	m	m	/	у	у	у	У
Date of end of event:			d	d	/	m	m	/	У	У	У	У
Detailed clinical descr	iption (for multiple	events	please desc	ribe s	ера	ratel	y):					
Diagnosis:												
Management and fina	al outcome:											
oid the patient report stackine Fluenz Tetra ®?	symptoms stated al	oove bet	fore vaccina	tion \	with	live	atter	nuat	ed i	nflue	enza	1
Yes			No									
rate describitions		12		1.	1	1! .		2				
t the time of the even Yes ▼	t, was the patient to	aking an	No No	cribe	ea m	ealc	atior	1:				_
	dia - f d d		INO									
If YES , list drugs inclu	ding form and dose	2:					_					
Drug			Form				Dos	se				
												_
												_
at the time of the even OTC) or herbal therapi		nown to	be taking f	ood s	upp	leme	ents,	Ove	r-Th	e-Co	ount	:er
Yes ▼	□ No				DK							
If YES , list products:												
ist any relevant past m	nedical history inclu	ıding re	cent immun	isatio	ns a	nd n	nedi	cal c	ond	ition	ıs:	





GP FOLLOW-UP QUESTIONNAIRE

Do you think the event was related to the vaccination?

Yes		No ▼		DK	
If NO , was another caus	se establi	shed?:			
Yes ▼		No		DK	
If YES , specify cause of	event:				
Provide the batch number of the Fluenz Tetra® vaccine administered to the patient, if known:					
Lot:					
Please return this questionnaire and copies of any relevant hospital correspondence in the FREEPOST envelope provided.					

Thank you for your assistance.

